CADL Stock Alert: Why Atlantic Trading Flagged Candel Therapeutics as a Swing Trade Opportunity

I added CADL (Candel Therapeutics) to my swings watchlist on March 20, 2026. The stock was added to my watchlist based on a compelling clinical pipeline with multiple shots on goal.

The company’s lead asset, CAN-2409 (aglatimagene), is an immunotherapy designed to trigger the immune system to attack cancer across several tumor types.

The most advanced programme is in prostate cancer, where the Phase 3 trial demonstrated approximately a 30% reduction in recurrence or death risk, with a BLA regulatory filing planned for Q4 2026 (a near-term, binary catalyst worth watching).

In lung cancer (NSCLC), earlier studies showed tumor shrinkage and signs of durable benefit, with the Phase 3 trial set to begin Q2 2026 (a likely defining moment for the company’s valuation).

The pancreatic cancer programme remains in its early stages but adds long-term upside optionality.

Critically, the company was well-funded following a recent public offering that extended its cash runaway through late 2027, removing near-term dilution risk from the equation.

At the chart level, CADL had pulled back to a clear area of support where significant buying pressure was visible. That kind of accumulation at a key level is a strong indicator that selling pressure is exhausted and a trend reversal may be incoming.

Combined with the fundamental backdrop (a de-risked balance sheet, a Phase 3 readout on the horizon, and a BLA filing approaching) the technical setup aligned well with the long-term story.

This was a strong indicator that the trend of the stock is about to reverse.

On March 23, 2026, CADL was alerted to Atlantic Trading premium members as a swing entry opportunity, with full information provided on the setup and the reasoning behind it, and provided information relating to the stock.

On May 15th, 2026, updates about the target price were shared ($10) along with new news reports about the company.

I finally completed this swing trade on June 29, 2026, at the exit price $10.31.